StockData

KORU Medical Systems vs Retractable Technologies

KRMD and RVP side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KRMD and RVP compare

KORU Medical Systems is the larger company, worth 9.5 times as much as Retractable Technologies ($161M against $16.9M).

KORU Medical Systems grew revenue faster over the last twelve months (22.4% versus −11.2% for Retractable Technologies).

KORU Medical Systems keeps more of each dollar of sales as profit, with a net margin of −4.0% compared with −9.9% at Retractable Technologies.

KORU Medical Systems scores higher on the StockData Score (12 against 11 for Retractable Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKRMDRVP
Size and price
Market cap$161M$16.9M
Share price$3.49$0.565
Change, 1 year−19.2%−27.4%
Change, 5 years−4.4%−93.5%
Beta (5Y)1.090.39
Employees73201
StockData Score
Total score12 (better)11
Valuation score03 (better)
Growth score3 (better)1
Performance score33
Health score6 (better)4
Dividend score00
Valuation
P/S3.6×0.5× (better)
P/B8.9×0.2× (better)
P/FCF207×–
FCF yield0.48%–
Fair value$2.67$3.11
Margin of safety−30.9%81.8% (better)
Growth
Revenue growth (TTM)22.4% (better)−11.2%
Revenue growth, 5Y average11.2% (better)−14.1%
Profitability
Gross margin62.4% (better)−1.4%
Operating margin−3.7% (better)−66.9%
Net margin−4.0% (better)−9.9%
FCF margin1.7%–
Return on equity−10.5%−4.5% (better)
Return on invested capital−14.3% (better)−24.8%
Financial health
Debt / equity0.000.00
Interest coverage–−278.8×
Current ratio2.724.93 (better)
Altman Z-score10.07 (better)0.43
Piotroski F-score55
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions44.5%8.8%
Held by insiders17.6%55.7%
Insider net buying, 12 months$1.6M (better)$0
Short interest, % of float2.3%0.17%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.